Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting...
CLEAR is Under Construction in Epic Toolbox in Identity Verification for EpicCare Link to Streamline Provider Access, Boost Security Integration will bring CLEAR’s identity verification platform to community-based providers, enhancing account creation and recovery workflows in EpicCare Link NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), the secure identity company, announced today that CLEAR1 is category, expanding its identity verification capabilities to support community health providers and affiliated staff. By continuing to integrate with Epic, CLEAR1 will bring se...
Figure 1. 2Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusAirbnb reported strong 2Q results and provided an in-line outlook for 3Q. Nights and Experiences booked growth in 2Q of +7.4% Y/Y was ~80bps above Street estimates. Revenue and adj. EBITDA were ahead of estimates by
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday, August 13, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To...
Figure 1. 2Q25 Results vs. ExpectationsSource: Company reports, Wedbush estimates, FactSet consensusClear reported 2Q results ahead of estimates. Bookings growth of +13.1% Y/Y in 2Q was approximately 260bps above consensus, and Clear delivered adj. EBITDA of $60.1mm (27.4% margin), exceeding the St
CLEAR Announces Second Quarter 2025 Financial Results NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clear Secure, Inc. (NYSE: YOU), the secure identity platform, has released financial results for the second quarter of fiscal year of 2025 on its Investor Relations website at . Second Quarter Financial Highlights(percentage change is expressed as year-over-year, unless otherwise specified) Revenue of $219.5 million was up 17.5%; Total Bookings of $222.9 million were up 13.1%Operating income of $42.6 million, representing a 19.4% Operating income marginNet income of $37.9 million, represent...
CLEAR Joins White House and CMS Effort to Power an Interoperable, Secure Digital Health Ecosystem As the IAL2 identity layer for major healthcare partners, CLEAR supports CMS’s nationwide initiative to modernize care through trusted, interoperable technologies NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), the secure identity platform, is participating in the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem initiative, a nationwide effort to deliver a more connected, patient-centered healthcare system. CLEAR was proud to stand alongside government, h...
Key Findings:US hotel RevPAR growth has averaged -0.4% Y/Y in 2Q, from +2% Y/Y in 1Q and +4% Y/Y in 4Q24. Growth fell ~1% Y/Y in June after flat Y/Y growth (~0%) in both May and April. Trends are slightly more positive on a 2-year stacked basis, with RevPAR growth averaging +1% Y/Y in 2Q, consisten
Alpine Income Property Trust Reports Second Quarter 2025 Operating and Financial Results WINTER PARK, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company” or “PINE”), an owner and operator of single tenant net leased commercial income properties, today announced its operating results and earnings for the three and six months ended June 30, 2025. “We continued to effectively execute our strategy focused on accretive capital recycling and have supplemented it with opportunistic common stock repurchases during the first half ...
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will implement a 1-for-25 reverse stock split of the issued shares of the company’s common stock (the Reverse Stock Split), effective at 5:00 p.m. Eastern Time on July 25, 2025. The Reverse Stock Split was approved by the company’s stockholders at the com...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.